Stay updated with breaking news from Optune gio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NovoCure (NASDAQ: NVCR) has recently received a number of price target changes and ratings updates: 4/3/2024 – NovoCure had its price target lowered by analysts at Wells Fargo & Company from $49.00 to $42.00. They now have an “overweight” rating on the stock. 3/27/2024 – NovoCure had its “neutral” rating reaffirmed by analysts at Wedbush. […] ....
NovoCure (NASDAQ:NVCR – Get Free Report) had its target price lowered by investment analysts at Wells Fargo & Company from $49.00 to $42.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective indicates a potential upside […] ....
NovoCure (NASDAQ:NVCR – Get Free Report) and Minerva Surgical (NASDAQ:UTRS – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends. Institutional and Insider Ownership 84.6% of NovoCure shares […] ....
Wedbush reissued their neutral rating on shares of NovoCure (NASDAQ:NVCR – Free Report) in a report published on Wednesday, RTT News reports. The firm currently has a $21.00 price target on the medical equipment provider’s stock. Wedbush also issued estimates for NovoCure’s Q4 2025 earnings at ($0.36) EPS, FY2026 earnings at ($1.45) EPS and FY2027 […] ....
NovoCure (NASDAQ:NVCR) Price Target Raised to $24.00 at HC Wainwright theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.